15 stories found
A North Cork TD stated that broader geopolitical conflicts persist regardless of recent local political victories, highlighting ongoing domestic and international tensions.
The Irish Health Service Executive has officially approved funding coverage for Skyclarys, providing a vital treatment option for patients with the rare genetic disorder.
The Health Service Executive (HSE) is under increasing pressure to decide on the reimbursement of Skyclarys, a drug costing €280,000 per year. A North Cork man has threatened High Court action if the 'life-changing' drug is not reimbursed.
Irish TDs are calling on a pharmaceutical company to collaborate with the HSE to make the life-changing drug Skyclarys available, despite its high annual cost of €288,000 per patient.
Patients suffering from Friedreich’s Ataxia have encountered a significant setback after the HSE Drugs Group rejected reimbursement for the drug Skyclarys. The recommendation will now proceed to a meeting of HSE senior management on August 25 for a final decision, offering a glimmer of hope.
The Skyclarys campaign highlights flaws in Ireland's drug reimbursement system, arguing it prioritizes bureaucratic and pharmaceutical interests over timely patient access to life-saving medications.
The Irish Health Service Executive is expected to announce whether it will fund Skyclarys (omaveloxolone), a recently approved medication for a rare genetic condition. The pending decision impacts patient access to life-changing therapy in Ireland.
Advocates and politicians are pressing the government and the HSE to reimburse the cost of Skyclarys, a life-changing drug for Friedreich’s ataxia, as patients suffering from the rare disease plead for access to the medicine.
The vast majority of Fianna Fáil parliamentary party members have signed a letter expressing serious concerns about a HSE group's recommendation to refuse funding for Skyclarys. Skyclarys is a drug used to treat the degenerative disease Friedreich's Ataxia.
Ireland's HSE Drugs Group is scheduled to meet to further consider whether to cover the cost of Skyclarys, a drug designed to slow the progression of Friedreich's Ataxia.
The Health Service Executive has approved financial reimbursement for a North Cork family following the use of the experimental gene therapy drug Skyclarys.
More than a thousand people gathered in Mallow, North Cork, to attend a vigil as part of a protest related to Skyclarys.
As patients with Friedreich's ataxia await a decision on Skyclarys, there is a call for Ireland to rethink and increase transparency in its process for assessing costly medicines.
The HSE Drugs Group made the recommendation following a meeting to consider an application for the reimbursement of Skyclarys.
Portugal's national health service has authorized two new treatments: Skyclarys for Friedreich's ataxia and Voranigo for Grade 2 brain tumors in adults and adolescents.